U.K. will fund a late-stage trial of Novavax’s vaccine candidate


The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Novavax, J&J Ink Covid-19 Vaccine Deals With U.K. for Tens of Millions of Doses

Source: WSJ

By Jonathan D. Rockoff and Jared S. Hopkins

U.K. will fund a late-stage trial of Novavax’s vaccine candidate, whle J&J agreed to provide 30 million doses

Novavax Inc. NVAX +11.39% and Johnson & Johnson JNJ +0.58% said Friday they have agreed to provide tens of millions of doses of their experimental coronavirus vaccines to the U.K. for undisclosed sums, as countries move to secure supplies of the shots.

Under the terms, the U.K. will fund a late-stage trial of Novavax’s vaccine candidate starting this quarter evaluating the shot in the country’s residents, and a contract manufacturer will make a key part of the vaccine at a plant in Stockton-on-Tees in northeast England, the company said Friday.

The contract manufacturer, a partnership between Fujifilm Corp. and Mitsubishi Corp., named Fujifilm Diosynth Biotechnologies, will also make extra supplies that Novavax could provide in other markets, the vaccine maker said.

“It is encouraging that Novavax’s recent clinical data shows their vaccine triggers an immune response greater than that in patients who have recovered from the disease,” said Kate Bingham, chair of the U.K. government’s vaccines task force.

In a small number of healthy volunteers in early-stage testing, the Novavax vaccine generated promising immune responses and was generally well-tolerated.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters


Coronavirus Vaccine Tracker – The New York Times

Categories: The Muslim Times

6 replies

  1. Novavax shares rose Friday after the company said it reached a deal with the U.K. to supply 60 million doses of its potential coronavirus vaccine.

    Novavax did not disclose the financial terms of the agreement. As part of the deal, the U.K. will collaborate with the company on its phase three clinical trial, which is expected to begin this quarter. The potential vaccine, named NVX-CoV2373, will be tested on around 9,000 adults between ages 18 and 85, the company said.

    Shares of Novavax were up more than 8% in midday trading.

    “We are honored to partner with the UK government to deliver a vaccine that could provide vital protection in the fight against the global health crisis,” Novavax CEO Stanley Erck said in a release Friday. “Our Phase 3 clinical trial in the UK will be a critical component to assess the efficacy of NVX-CoV2373, which in a Phase 1 trial has already demonstrated to be generally well-tolerated and to elicit robust antibody responses.”

    The company already has a deal with the U.S. government. Last month, the Trump administration’s Operation Warp Speed initiative announced it would pay Novavax $1.6 billion to develop and manufacture the potential vaccine, with the aim of delivering 100 million doses by the beginning of next year.

    Novavax’s vaccine contains synthesized pieces of the surface protein the coronavirus uses to infect humans.


  2. Five analysts forecast the average price in 12 months at $227.60 with a high forecast of $290.00 and a low forecast of $105.00. The average price target represents a 70.77% increase from the last price of $133.28. From those five, four analysts rated ‘Buy’, none analyst rated ‘Hold’ and one rated ‘Sell’, according to Tipranks.

    H.C. Wainwright raised their 12-month price target to $290 from $132 and JP Morgan upped it to overweight from neutral, raising the target price to $275 from $105. We think it is good to buy at the current rate and target $227 as 100-day Moving Average and 100-200-day MACD Oscillator signal a strong buying opportunity.


  3. The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

    Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.

    The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.

    Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

    Novavax will supply the NVX-CoV2373 doses to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.

    The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.

    The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.

    There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.


  4. Novavax will supply the U.K. with 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The biotech is also planning a phase 3 study to test the effectiveness of the vaccine among participants from the U.K.

    “It is encouraging that Novavax’s recent clinical data shows their vaccine triggers an immune response greater than that in patients who have recovered from the disease,” said Kate Bingham, Chair of the U.K. Government’s Vaccines Taskforce. “We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options.”

    Novavax is also broadening its partnership with Fujifilm Diosynth Biotechnologies, which will help manufacture as much as 180 million doses annually of NVX-CoV2373 from a site in the U.K. if the vaccine is shown to be safe and effective.

    Phase 1 data from Novavax’s clinical trial was promising — NVX-CoV2373 induced a robust antibody response in patients and was generally well-tolerated. Novavax expects to begin a phase 2 study later this month.

    The phase 3 clinical trial in the U.K. will include as many as 9,000 participants aged 18 to 85. It will test the effectiveness of NVX-CoV2373 against COVID-19, as well as observe its ability to produce antibody and T-cell responses in the human body. The study is expected to begin in the third quarter.

    Novavax’s agreement with the U.K. follows deals with the U.S., Japan, India, and South Korea in recent weeks. “We are honored to partner with the U.K. government to deliver a vaccine that could provide vital protection in the fight against the global health crisis,” Novavax CEO Stanley Erck said.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.